Amgen Inc. $AMGN Stock Sold by Philadelphia Trust Co.

Philadelphia Trust Co. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 9.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 33,164 shares of the medical research company’s stock after selling 3,632 shares during the period. Amgen accounts for about 0.9% of Philadelphia Trust Co.’s investment portfolio, making the stock its 28th biggest holding. Philadelphia Trust Co.’s holdings in Amgen were worth $13,979,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. State Street Corp lifted its holdings in Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. Bank of America Corp DE purchased a new stake in shares of Amgen during the 2nd quarter worth $1,831,903,000. Wellington Management Group LLP boosted its position in shares of Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares in the last quarter. BlackRock Inc. grew its stake in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Amgen by 702.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after purchasing an additional 1,344,010 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $465.23 on Wednesday. The company has a market capitalization of $251.65 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 3.25 and a beta of 0.43. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The firm has a 50-day moving average price of $423.79 and a 200 day moving average price of $379.39. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $5.64 EPS. Research analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is currently 58.47%.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on AMGN shares. Wells Fargo & Company raised their price objective on shares of Amgen from $430.00 to $460.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. UBS Group upped their target price on shares of Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their price target on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Finally, Freedom Broker downgraded shares of Amgen from a “buy” rating to a “hold” rating and lifted their price target for the company from $450.00 to $470.00 in a research report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $422.76.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.